William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.
Separately, UBS Group began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They issued a “buy” rating and a $21.00 price target on the stock.
Get Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 0.5 %
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- How to Calculate Options Profits
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 11/18 – 11/22
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
